UBIGENE

Comprehensive CRISPR Gene Editing Solutions to Power Your Research: KO Cell Lines, CRISPR Screen & More

Gene Point Mutation Cell Line Service

Start at $4980 | 6 Wks deliver homozygous clone | HDR up to 84%

Chat with an Expert

Gene Point Mutation Cell Line

Gene point mutation cell lines are generated by co-delivering, via nucleofection, ribonucleoprotein (RNP) complexes composed of gRNA and Cas9 protein together with a single-stranded oligonucleotide (ssODN) donor harboring the desired point mutation into cells. Subsequently, single-cell clones are isolated using the limiting dilution method. Following the induction of DNA double-strand breaks (DSBs) at the target locus by the RNP complex, cells utilize the ssODN donor as a repair template to perform homology-directed repair (HDR), thereby precisely incorporating the intended point mutation into the genomic target site. The target region is then amplified and validated by sequencing to identify and screen positive mutant clones.

EZ-HRex™ Technology (High HDR Efficiency)
After several years of innovation, Ubigene has advanced its proprietary EZ-editor™ platform by introducing the novel U+ molecule, resulting in the upgraded EZ-HRex™ technology. This enhancement markedly improves homology-directed repair (HDR) efficiency for both precise point mutations and fragment knock-in applications. Following transfection, the proportion of HDR-edited genotypes at the cell pool level can reach up to 84%.
EZ-HRex™ Technology Highlights
Effectively regular cell cycles, promoting more post-transfection cells into S/G2 phases.
Reduce the NHEJ pathway activity, reducing the proportion of indel genotype to improve the HDR efficiency.

Point Mutation Cell Line Service Detail

Service Type

Gene Point Mutation

Cell Line Type

Tumor Cells, Immortalized Cell Lines. Various cell types, including iPS cells

Project Price (USD)

From $4980

Turnaround

As fast as 6 weeks

Deliverables

1. ≥1 homozygous Single Clone(>106 cells/vial, 2 vials per clone) 2. Wild-Type Cells(>106 cells/vial, 2 vials) 3. Experimental Reports

Point mutation validation

PCR(Standard), Sanger sequencing(Standard)

* For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
300+ Successful Gene-editing Cell Line Types

Digestive System

Human Gallbladder Carcinoma Cell Line (GBC-SD)Human Hepatoma Cell Line (Hep G2)Human Hepatoma Cell Line (SNU-387)Human Hepatoma Cell Line (HuH-7)Human Hepatoma Cell Line (SK-HEP-1)Human Hepatoma Cell Line (Hep 3B)Human Normal Hepatocytes Cell line (L-02)Human Colon Cancer Cell Line (HCT 116)Human Colon Cancer Cell Line (HT-29)Human colorectal adenocarcinoma Cell Line (RKO)Human colorectal adenocarcinoma Cell Line (Caco-2)Human Esophageal Squamous Carcinoma Cell Line (KYSE-150)Human gastric cancer Cell Line (AGS)Mouse Hepatocarcinoma Cell Line (Hepa 1-6)Murine colorectal carcinoma Cell Line (CT26.WT)Murine colorectal carcinoma Cell Line (MC38)Human Esophageal Squamous Carcinoma Cell Line (KYSE-30)Mouse Hepatocarcinoma Cell Line (H22)Human Gastric Cancer Cell Line (NCI-N87)Human colorectal adenocarcinoma Cell Line (SW480)Human Hepatoma Cell Line (SMMC-7721)Porcine intestinal epithelial Cell Line (IPEC-J2)Human Gastric Cancer Cell Line (HGC-27)Human Gastric Cancer Cell Line (MGC-803)Human renal carcinoma cell line (ACHN)Human colorectal adenocarcinoma Cell Line (LS 174T)Immortalized Human Hepatic Cell Line (C3A)Human Hepatoma Cell Line (PLC/PRF/5)Human colorectal adenocarcinoma Cell Line (SW 48)Human colorectal adenocarcinoma Cell Line (SW948)Human colorectal adenocarcinoma Cell Line (NCI-H716)Mouse hepatocyte Cell Line (AML12)Human Gastric Cancer Cell Line (SGC-7901)Human Ileocecal Cancer Cell Line (HRT-18)Human Colon Cancer Cell Line (LoVo)Human Hepatoma Cell Line (MHCC97-H)Human Gastric Cancer Cell Line (MKN-45)Human Colon Cancer Cell Line (COLO 205)Rat Liver Cell Line (BRL)Mouse Gastric Cancer Cell Line (MFC)Human Colon Cancer Cell Line (SW620)Human Hepatoma Cell Line (Li-7)Mouse Ascites Sarcoma Cell Line (S180)Rat Liver Cell Line (BRL-3A)Human Colon Cancer Cell Line (HCT-15)Human Gastric Cancer Cell Line (KATO III)Human colorectal adenocarcinoma Cell Line (SW1463)Human Gastric Cancer Cell Line (SNU-5)Human colorectal adenocarcinoma Cell Line (SW1116 [SW 1116, SW-1116])Human Hepatic Stellate Cell Line (LX-2)Human Hepatoma Cell Line (HCCLM3)

Endocrine System

Human Submandibular Gland Epidermoid Carcinoma Cell Line (A-253)Human Mammary Epithelial Cell Line (MCF 10A)Human Breast Cancer Cell Line (MDA-MB-231)Human Breast Cancer Cell Line (MCF7)Human Breast Cancer Cell Line (MDA-MB-415)Human Breast Cancer Cell Line (MDA-MB-468)Human Breast Epithelial Cell Line Integrating SV40 Gene (HBL-100)Human Prostate Cancer Cell Line (LNCaP Clone FGC)Human Prostate Cancer Cell Line (PC-3)Human Prostate Cancer Cell Line (22RV1)Human pancreatic cancer Cell Line (BxPC-3)Mouse Breast Cancer Cell Line (4T1)Mouse Acinar Pancreatic Cell Line (266-6)Human Breast Cancer Cell Line (JIMT-1)Mouse prostate cancer Cell Line (RM-1)Human Breast Cancer Cell Line (SK-BR-3)Human Breast Cancer Cell Line (HCC1806)Human Thyroid Normal Cell Line (Nthy-ori 3-1)Mouse pancreatic cancer Cell Line (Pan-02)Human Pancreatic Carcinoma Cell Line (SW1990)Human acute lymphoblastic leukemia Cell Line (MOLT4)Human Pancreatic Carcinoma Cell Line (Panc-1)Mouse Breast Adenocarcinoma Cell Line (E0771)Human Thyroid Squamous Cell Carcinoma Cell line (SW579)Human Breast Cancer Cell Line (HCC1143)Human breast cancer Cell Line (BT-549)Human acute lymphoblastic leukemia Cell Line (MT-4)Py230 Cell Line (Py230)Human Thyroid Cancer Cell Line (TPC-1)Human Prostate Cancer Cell Line (PC-3M)Human Burkitt's Lymphoma Cell Line(RAJI)Human Metastatic Pancreatic Adenocarcinoma Cell Line (AsPC-1)Human NK Leukemia Cell Line (YT)Human Prostate Cancer Cell Line (DU145)Mouse Mammary Epithelial Cell Line (HC11)Mouse Breast Cancer Cell Line (C127)Human Thyroid Normal Cell Line (Nthy-ori 3-1)Human Pancreatic Carcinoma Cell Line (MIA PaCa-2)Mouse Breast Cancer Cell Line (EMT6)Human Prostate Cancer Cell Line (VCaP)Human Breast Cancer Cell Line (SUM-149PT)Human breast ductal cancer cell Line (BT474)Human Pancreatic Carcinoma Cell Line (Capan2)

Respiratory System

Human Lung Cancer Cell Line (A549)Human Lung Cancer Cell Line (NCI-H1299)Human Lung Cancer Cell Line (NCI-H520)Human Lung Cancer Cell Line (SK-MES-1)Mouse Lewis lung carcinoma Cell Line (LLC)Human Bronchial Epithelial Cell Line (BEAS-2B)Human Lung Cancer Cell Line (HCC827)Porcine alveolar macrophage cell line (3D4/21)Human lung adenocarcinoma Cell Line (PC9)Human Lung Cancer Cell Line (NCI-H1650)Human Lung Cancer Cell Line (NCI-H727)Human lung adenocarcinoma Cell Line (NCI-H1975)Human lung cancer Cell Line (NCI-H292)Human Lung Cancer Cell Line (NCI-H23)Human Lung Cancer Cell Line (MSTO-211H)Human Lung Cancer Cell Line (NCI-H358)Human Non-small Cell Lung Carcinoma Cell Line (NCI-H460)Human lung adenocarcinoma Cell Line (Calu-3)Human Fetal Lung Fibroblast Cell Line (MRC-5)Human Highly Metastatic Lung Cancer Cell Line (95-D)Human Colon Carcinoma Cell Line (T84)MLE-12 Cell Complete Medium (MLE-12)Human Fetal Lung Fibroblast Cell Line (WI-38)Human Lung Cancer Cell Line (DMS114))Human lung adenocarcinoma Cell Line (NCI-H1373)Human Lung Cancer Cell Line (NCI-H1703)Human Lung Cancer Cell Line (DMS 53)Human Small Cell Lung Cancer Cell Line (NCI-H82 [H82])Human Small Cell Lung Cancer Cell Line (SHP-77)Human Lung Cancer Cell Line (NCI-H2170)

Reproductive System

Human Amniotic Cell Line (WISH)Human Highly Metastatic Ovarian Cancer Cell Line (HO-8910PM)African green monkey kidney Cell Line (Marc-145)Human Cervical Carcinoma Cell Line (Hela)Human ovarian cancer Cell Line (OVCAR-3)Human Ovarian Adenocarcinoma Cell Line (Caov-3)Mouse Embryonic Fibroblasts (NIH/3T3)Mouse Fibroblast Cell Line (TM3)Human Villous Trophoblast (HTR-8/SVneo)Human Ovarian Granulosa Cell Line (KGN)Chinese Hamster Ovary Cell Line (CHO-K1)Human Endometrial Adenocarcinoma Cell Line (MFE-280)Mouse ovarian epithelial cancer Cell (ID8)Human endometrial adenocarcinoma Cell (HEC-1-B)Human Endometrial Carcinoma Cell Line (ISHIKAWA)Human Cervical Carcinoma Cell Line (C-33 A)Human Cervical Carcinoma Cell Line (Ca Ski)Human Endometrial Carcinoma Cell Line (KLE)Mouse Teratocarcinoma Cell Line (P19)Human Ovarian Clear Cell Carcinoma Cell Line (ES-2)Human Endometrial Adenocarcinoma Cell Line (AN3 CA)Human Cervical Carcinoma Cell Line (hela 229)Human Ovarian Adenocarcinoma Cell Line (SK-OV-3)Human Choriocarcinoma Cell Line (Bewo)

Circulatory System

Rat Cardiac Myocytes (H9c2(2-1))Mouse Myoblast Cell Line (C2C12)Human Cardiac Myocytes (AC16)Mouse Aortic Smooth Muscle Cell Line (MOVAS)

Blood and lymphatic System

Mouse Hybridoma Cell Line (AE-1)Hybridoma (Anti-Cd3) Cell Line (OKT 3)Human Monocytic Cell Line (THP-1)Human Histiocytic Lymphoma Cell Line (U-937)Human T Lymphocyte Cell Line (Jurkat, Clone E6-1)Human Acute Lymphocyte Cell Line (OCI-Aml-3)Human myelogenous Leukemia Cell Line (K-562)Mouse Macrophage Cell Line (RAW 264.7)Human Acute Promyelocytic Leukemia Cell Line (HL-60)Human B Lymphoma Cell Line (U-2932)Mouse B Lymphoma Cell Line (A20)Human Myelomonocytic Leukemia Cell Line (MV4-11)Human B Lymphoma Cell Line (SU-DHL-4)Human Acute Myeloid Leukemia Cell Line (KG-1a)Human Erythroleukemia Cell Line (HEL)Mouse Pro B Cell Line (BAF3)Human acute promyelocytic leukemia cell line (NB4)Human T-lymphocyte Cell Line (Hut-78)Human B Lymphocytes Cell Line (GM12878)Mouse Lymphoma Cell Line (EL4)Mouse Macrophage Cell Line (Ana-1)Human Erythroleukemia Cell Line (TF-1)Human Lymphoma Cell Line (BC-3)Human Multiple Myeloma Peripheral Blood B Lymphocytes (RPMI 8226)Human Burkitt's Lymphoma B Lymphocytes (Ramos)Human B lymphoma cell line (SU-DHL-6)Human Acute Lymphoblastic Leukemia Cell Line (Non-B Non-T)(Reh)Human Acute Lymphocyte Cell Line (Kasumi-1)Human Mantle Cell Lymphoma Cell Line (JeKo-1)Human peripheral blood mantle lymphoma Cell Line (Mino)Human Acute Myeloid Leukemia Cell Line (MOLM13)Human B lymphocytic leukaemia Cell Line (NALM-6)Human B lymphoma Cell Line (SU-DHL-8)

Brain and Nervous System

Rat Glioblastoma Cell Line (C6)Mouse Hippocampal Neuronal Cell Line (HT-22)Human Neuroblastoma Cell Line (SK-N-SH)Human Neuroblastoma Cell Line (SH-SY5Y)Human glioblastoma Cell Line (U-87 MG)Human glioblastoma Cell Line (U251MG)Mouse Anterior Parietal Bone Cell Line (MC3T3-E1 Subclone 14)Mouse microglia Cell Line (BV2)Human microglial clone 3 Cell Line (HMC3)Mouse neuroblastoma Cell Line (Neuro-2a)Human glioblastoma Cell Line (LN-229)Mouse Glioblastoma Cell Line (GL261)Human Glioblastoma Cell Line (T98G)Human Glioblastoma Cell Line (A-172)Human Neuroblastoma Cell Line (SK-N-BE(2))Human Brain Astrocytoma Cell Line (Hs 683)Rat Glioblastoma Cell Line (RG2)

Urinary System

African green monkey kidney Cell (Vero)African green monkey kidney Cell (VERO C1008 (E6))Dog Kidney Cell Line (MDCK(NBL-2))Human Embryonic Kidney Cell Line (293T)Human Embryonic Kidney Cell Line (293T)Human Embryonic Kidney Cell Line (HEK293)Rat adrenal pheochromocytoma Cell Line (Low differentiation)(PC-12)Human Bladder Transitional Cell Carcinoma Cell Line (T24)Human bladder carcinoma cell line (5637)Mouse Bladder Cancer Cell (MB-49)Human renal cell carcinoma Cell Line (786-0)Human renal cell carcinoma Cell Line(MS751)Mouse podocyte Cell Line(MPC-5)Pig Kidney Cell line(PK-15)Human Embryonic Kidney Cell Line (2V6.11)Human Bladder Transitional Cell Carcinoma Cell Line (SW780)Transformed (SV40) African Green Monkey Kidney Cell Line (COS-1)Transformed (SV40) African Green Monkey Kidney Cell Line (COS-7)Rat Kidney Cell Line (NRK-52E)Mouse Renal Adenocarcinoma Cell Line (RenCa)Bovine Kidney (MDBK) Cell Line (MDBK (NBL-1))Hamster Kidney Fibroblasts (BHK-21)Human Renal Proximal Tubular Epithelial Cell Line (HK-2)Human Urinary Bladder Squamous Cell Carcinoma Cell Line (SCaBER)Mouse Renal Adenocarcinoma Cell Line (RAG)Mouse Bladder Cancer Cell (MBT-2)Human renal carcinoma Cell Line (OS-RC-2)

Skeleton, Articulus, Soft Tissue, Derma System

Human Umbilical Vein Cell Line (EA.hy926)Mouse Lewis lung carcinoma Cell Line (U-2 OS)Human Osteosarcoma Cell Line (Saos-2)Human skin squamous carcinoma Cell Line (A-431)Murine melanoma Cell Line (B16-F10)Human malignant melanoma Cell Line (A-375)Human Skin Fibroblast Cell Line (BJ)Mouse Fibroblast Cell Line (L-929)Mouse Lewis lung carcinoma Cell Line (SW 1353)Human fibrosarcoma Cell Line (HT-1080)Rat osteosarcoma Cell Line(UMR-106)Human Immortalized Keratinocytes Cell Line (HaCaT)Chicken Fibroblast Cell Line (DF1)Human Multiple Myeloma Cell Line (MM.1S)Human Corneal Epithelial Cell Line (HCE-T)(HCE-T)Immortalized Human Lens Epithelial Adherent Cell Line (SRA01/04)Mouse Lewis lung carcinoma Cell Line (MG-63)Mouse Osteosarcoma Cell Line (K7M2-WT)Mouse Lewis lung carcinoma Cell Line (143B)Mouse Subcutaneous Connective Tissue Cell Line (A9)Mouse squamous carcinoma Cell Line (SCC-7)Human Choriocarcinoma Cell Line (JAR)Human bone osteosarcoma epithelial Cell Line (KHOS-240S)Mouse Chondrogenic Cell Line (ATDC5)

Stem Cell Lines

Human induced pluripotent stem cells (iPSC) (IPSC-DYR0100)

Ocular, Otolaryngologic and Oral System

Human Pharyngeal Carcinoma Cell Line (Pleural Effusion Metastasis) (Detroit 562)Human retinal pigment epithelial Cell Line (ARPE-19)Human Nasopharyngeal Carcinoma Cell Line (CNE1)Human oral squamous carcinoma Cell Line (HSC3)Human nasopharyngeal carcinoma Cell Line (HK-1)Human oral squamous carcinoma cell line (CAL-27)Mouse Cochlear Hair Cell Line (HEI-OC1)Human Retinoblastoma Cell Line (Y79)Human Tongue Squamous Carcinoma Cell Line (SCC-9)Human Pharyngeal Squamous Cell Carcinoma Cell Line (FaDu)

Point Mutation (PM) Cells Construction Methods

4 solutions to meet different mutation needs!

RNP

Incubate sgRNA and Cas9 protein in vitro to form an RNP (ribonucleoprotein) complex, which is then co-transfected into cells along with a single-stranded oligonucleotide. After the RNP induces a double-strand break at the target site, the oligonucleotide can introduce the desired mutation into the genomic target through homologous recombination.

    Features:

  • Broad applicability
  • High editing efficiency
  • Short turnaround time

    Applicable Types:

  • Suitable when a gRNA sequence can be identified within approximately 10 bp of the mutation site.
  • Applicable to target cells that can be transfected using electroporation or liposome-based transfection.
Prime Editor

Gene editing is achieved by fusing an engineered reverse transcriptase with a Cas9 nickase and using a special prime editing guide RNA (pegRNA).

    Features:

  • Capable of correcting various complex mutations.
  • However, it has low editing efficiency and requires complex vector design.

    Applicable Types:

  • Suitable for correcting complex mutations.
  • Ideal for cases where an appropriate gRNA sequence cannot be found near the mutation site.
Base Editing

A base editing system is developed by integrating a base deaminase with the CRISPR/Cas system, enabling precise introduction of C/G-to-T/A and A/T-to-G/C point mutations without creating double-strand breaks, thereby achieving highly efficient and accurate gene editing.

    Features:

  • High efficiency, but applicable cases are limited.

    Applicable Types:

  • Suitable for specific single-base conversions (C⇌T; A⇌G) when the target site is within the active window.
Antibiotics-based Konck-in

The donor vector is constructed using a plasmid, with a resistance gene expression cassette inserted into an intron to enhance the efficiency of point mutation recombination through antibiotic screening.

    Features:

  • Suitable for scenarios where a suitable gRNA sequence cannot be identified near the mutation site; however, it is relatively expensive and has a longer experimental cycle.

    Applicable Types:

  • Ideal for cases where a suitable gRNA sequence cannot be identified near the mutation site.

Workflow and Validation

01

Strategy Design by Red Cotton System

02

RNP Complex

03

Cell Transfection

04

Pool Efficiency Validation

05

Single-cell Cloning

06

PCR Amplification

07

Sanger Sequencing Validation

08

QC & Cell Cryopreservaion

Case Study

HDR Efficiency (%)

48 %

HUVEC

50 %

iPSC

62 %

HuH-7

84 %

HEK293

data

EZ-HRex™

Traditional Method

table
Figure 1. The EZ-HRex™ technology has been evaluated for HDR efficiency across multiple cell types, demonstrating a 5-10-fold improvement compared with conventional genome editing approaches.
Figure 2: EEF1A1 knockin A549 cell pool was generated using the EZ-HRex™ technique, with an HDR efficiency reaching 88%.
(A)
(B)
Figure 3: Validation of point mutations in THP-1 cells. (A) Point mutations were verified by Sanger sequencing. (B) Genotyping PCR analysis of homozygous point mutation clones.

Featured Citations

A549 Cell MYC Gene - Lung Cancer

IF=20.8

Nature Metabolism

Acetate reprogrammes tumour metabolism and promotes PD-L1 expression and immune evasion by upregulating c-Myc

Zhejiang University and the Chinese Academy of Medical Sciences
Abstract:
This study demonstrated that acetate is the most abundant short-chain fatty acid in human non-small cell lung cancer tissue, with increased acetate uptake as the tumors enriched. The study used Ubigene-constructed MYC (p.K148R) point mutant A549 cells and MYC (p.K148Q) point mutant A549 cells, simulating acetylated and non-acetylated c-Myc states, and investigated the impact of these changes on tumor cell behavior. View details

View Picture

Figure 1 Mechanism pattern diagram

FOXP1 gene in HEK293 cells - Tumor occurrence

IF=9.4

The EMBO Journal

FOXP1 phosphorylation antagonizes its O-GlcNAcylation in regulating ATR activation in response to replication stress

Shenzhen University, Shenzhen University General Hospital
Abstract:
This study reveals a new mechanism by which the forkhead box (FOX) transcription factor FOXP1 promotes ATR-CHK1 activation under replication stress. This function does not rely on the transcriptional regulatory activity of FOXP1 but is instead co-regulated by its phosphorylation and glycosylation modifications. The study used the source cell lines from Genewell to construct the FOXP1 gene S396A and S396D point mutation HEK293 cell lines. View details

View Picture

Figure 2 Mechanism pattern diagram

FAQs

1. What is CRISPR point mutation?

CRISPR point mutation refers to using CRISPR/Cas9 technology to introduce a very specific, single-nucleotide change (A, T, C, or G) in the DNA sequence of a gene.

Instead of knocking out (deleting) a gene or inserting large DNA fragments (knock-in), point mutation precisely changes just one base pair. Scientists often use this to:

  • Correct disease-causing mutations
  • Create specific disease models
  • Study the function of a particular amino acid in a protein

This is usually achieved by combining CRISPR/Cas9 with a carefully designed donor template (a short DNA sequence with the desired mutation) that the cell uses during repair.

2. What are the 4 types of point mutations?

  • Substitution:
    One base is replaced by another.
    e.g. A changes to G.
  • Insertion:
    One extra base is inserted into the DNA sequence.
    e.g. An extra A is added between two bases.
  • Deletion:
    One base is removed from the DNA sequence.
    e.g. A single missing C.
  • Frameshift mutation (special case of insertion or deletion):
    When an insertion or deletion changes the reading frame of the gene.
    This can dramatically alter the resulting protein.

3. Are point mutations reversible?

Yes, especially with modern genetic technologies! Contact us now

There are 2 main lab strategies:

  • CRISPR knock-in: Introduce a donor template with the correct base.
  • Base editors: Use engineered CRISPR systems that can directly change one base to another without making a DNA break..

4. What are the applications of CRISPR point mutation?

  • Disease modeling
  • Gene function research
  • Therapeutic correction
  • Drug discovery and screening
  • Agriculture and biotechnology

Contact Us

Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours

* Name

* Email

* Institution

* Products & Services of Interest

If email is not available, how else can we reach you?

How did you hear about us?

Logo
E-mail: info@ubigene.com
WhatsAPP: +86 153 6067 3248
TEL: +86 153 6067 3248(Int'l)
Copyright © 2025 Ubigene. All rights reserved.